Adicet Bio, Inc. (LON:0HX7)
London · Delayed Price · Currency is GBP · Price in USD 7.55
+0.42 (5.85%)
Mar 13, 2026, 2:22 PM GMT
Adicet Bio Company Description
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.
The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen.
The company was founded in 2014 and is based in Boston, Massachusetts.
Adicet Bio, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 152 |
| CEO | Chen Schor |
Contact Details
Address: 131 Dartmouth Street Boston, Massachusetts 02116 United States | |
| Phone | 650 503 9095 |
| Website | adicetbio.com |
Stock Details
| Ticker Symbol | 0HX7 |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US0070022076 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chen Schor BA, CPA, M.B.A. | Chief Executive Officer, President and Director |
| Brian Nicholas Harvey | Chief Financial Officer |
| Dr. Blake Aftab Ph.D. | Senior Vice President and Chief Scientific Officer |
| Dr. Donald Healey Ph.D. | Chief Technology Officer |
| Amy Locke | Chief Human Resource Officer |
| Dr. Julie Maltzman M.D. | Chief Medical Officer |